Dear Madame, Sir,
Brussels, BELGIUM - July 24, 2006, Belgian biopharmaceutical company UCB will release its half year financial results for 2006 on Thursday July 27, 2006.
If you haven't subscribed for the press release service yet, you can still do so by clicking here: Once subscribed, you will receive all the UCB news at the same time as it is distributed to the financial professionals and news wires.
About UCB
UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, inflammatory diseases, and oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex® (antitussive) and Metadate(TM) / Equasym XL(TM) (attention deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels (UCB / UCBBt.BR / UCB BB).
For further enquiries, please contact
Jean-Christophe Donck
Vice President Corporate Communications and Investor Relations
+32 2 559 9588